12:00 AM
Jul 25, 1994
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Synergen Inc.


Cortech Inc.


Kemper Securities analyst Bharat Pandya maintained a "hold" on SYGN following the announcement that the company was stopping its second Phase III study of Antril IL-1 receptor antagonist to treat sepsis after the drug failed to show efficacy in an interim analysis.

Pandya said he was keeping his rating because SYGN...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >